Xilio Therapeutics (XLO) Profit After Tax (2020 - 2026)

Xilio Therapeutics has reported Profit After Tax for 7 years, with the latest figure at -$9.5 million in Q1 2026.

• Quarterly Profit After Tax rose 28.16% year-over-year to -$9.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$31.3 million (up 42.36% YoY) and the FY2025 annual result came in at -$35.0 million, up 39.84% from the prior year.
• Profit After Tax retreated to -$9.5 million in Q1 2026 per XLO's latest filing, from $10.4 million in the prior quarter.
• Over five years, Profit After Tax peaked at $10.4 million in Q4 2025 and troughed at -$24.6 million in Q2 2022.
• A 5-year average of -$15.7 million and a median of -$16.7 million in 2023 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2025: Profit After Tax retreated 28.12% in 2022, then jumped 179.13% in 2025.
• Over 5 years, Profit After Tax stood at -$22.4 million in 2022, then rose by 21.34% to -$17.7 million in 2023, then rose by 25.84% to -$13.1 million in 2024, then surged by 179.13% to $10.4 million in 2025, then tumbled by 191.98% to -$9.5 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$9.5 million, $10.4 million, and -$16.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.